论文部分内容阅读
目的探讨氟哌噻吨美利曲辛片治疗急性心肌梗死(AMI)早期溶栓治疗后伴抑郁患者的临床效果。方法选取2015年12月至2016年12月武汉科技大学附属天佑医院心血管内科收治的86例AMI早期溶栓治疗后伴抑郁患者作为研究对象,按随机抽签法分为试验组与对照组,各43例。两组患者均采用相同药物进行溶栓治疗,同时对照组患者采用安慰剂抗抑郁,试验组患者采用氟哌噻吨美利曲辛片抗抑郁,比较两组患者的临床效果。结果试验组患者梗死后心绞痛(PIA)发生率明显低于对照组,差异有统计学意义(P<0.05);两组患者再通率及不良反应发生率差异均无统计学意义(均P>0.05);治疗后,试验组患者抑郁自评量表(SDS)评分明显低于对照组,差异有统计学意义(P<0.05)。结论氟哌噻吨美利曲辛片治疗AMI早期溶栓后伴发抑郁患者疗效显著,可有效改善其抑郁症状,减少心脏不良事件发生。
Objective To investigate the clinical efficacy of flupenthixol and melitracen in the treatment of patients with depression after early thrombolytic therapy of acute myocardial infarction (AMI). Methods Eighty-six patients with AMI after thrombolytic therapy of AMI admitted to the Department of Cardiology, Sky-friendly Hospital Affiliated to Wuhan University of Science and Technology from December 2015 to December 2016 were selected as research subjects and divided into experimental group and control group by random sampling 43 cases. Patients in both groups were treated with thrombolytic therapy with the same drugs and placebo antidepressant in the control group. Flupenthixol and melitracen tablets were used in the test group to treat depression, and the clinical effect was compared between the two groups. Results The incidence of post-infarction angina pectoris (PIA) in the experimental group was significantly lower than that in the control group (P <0.05). There was no significant difference in the recanalization rate and incidence of adverse reactions between the two groups (P> 0.05). After treatment, the self-rating depression scale (SDS) score of the test group was significantly lower than that of the control group, the difference was statistically significant (P <0.05). Conclusion The efficacy of flupenthixol and melitracen in the treatment of patients with AMI after early thrombolysis with depression is significant, which can effectively improve the depressive symptoms and reduce the incidence of cardiac adverse events.